Herein, targeting USP7 for destabilizing MDM2/MDMX and activating p53 has recently been proposed as a promising strategy for cancer therapy, and several USP7 inhibitors have been developed and shown promising efficacy in preclinical cancer models in vitro and in vivo (Zhou et al., 2018). Here, MDM2 is linked to cancer.